Brian D. Harms

Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

Birgit Schoeberl, Emily A. Pace, Jonathan B. Fitzgerald et al. · Science Signaling · 2009 · 367 citations

Lessons Learned from Quantitative Dynamical Modeling in Systems Biology

Andreas Raue, Marcel Schilling, Julie Bachmann et al. · PLoS ONE · 2013 · 355 citations · Full text

Intuitive Interpretation, Engineering, Mathematical Biophysics +14

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Charlotte F. McDonagh, Alexandra Huhalov, Brian D. Harms et al. · Molecular Cancer Therapeutics · 2012 · 274 citations · Full text

Breast Oncology, Antitumor Activity, Immunology +18

Directional Persistence of EGF-Induced Cell Migration Is Associated with Stabilization of Lamellipodial Protrusions

Brian D. Harms, Gina M. Bassi, Alan Rick Horwitz et al. · Biophysical Journal · 2005 · 126 citations · Full text

Developmental Biology, Directional Persistence, Morphogenesis +10

MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

Jonathan B. Fitzgerald, Bryan W. Johnson, Jason Baum et al. · Molecular Cancer Therapeutics · 2013 · 102 citations

Immunology, Tumor Biology, Insulin-like Growth Factor +17